Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26491913 | 0.86 | ALDH1A1 (0.46) | CA9CA1CA12NPC1ALDH1A1 | |
| SCHEMBL15043753 | 0.82 | NR1H3 (0.58) | CA9CA1CA12NPC1ALDH1A1 | |
| SCHEMBL12464403 | 0.82 | CA1 (0.58) | CA9CA1CA12NPC1ALDH1A1 | |
| SCHEMBL19702942 | 0.81 | CA9 (0.53) | CA9CA1CA12NPC1ALDH1A1 | |
| SCHEMBL14072404 | 0.78 | NPC1 (0.53) | CA9CA1CA12NPC1ALDH1A1 | |
| SCHEMBL12235644 | 0.78 | CA9 (0.56) | CA9CA1CA12NPC1ALDH1A1 | |
| SCHEMBL2200817 | 0.77 | CA9 (0.49) | CA9CA1CA12NPC1ALDH1A1 | |
| SCHEMBL2156201 | 0.77 | CA9 (0.56) | CA9CA1CA12NPC1ALDH1A1 | |
| SCHEMBL20306714 | 0.76 | CA9 (0.55) | CA9CA1CA12ALDH1A1CA2 | |
| SCHEMBL15043752 | 0.75 | CA9 (0.58) | CA9CA1CA12NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| US-11117885-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210213012-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER | ACCUTAR BIOTECHNOLOGY INC. | 2021-07-15 | — | — | US | disclosed |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117885-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | CA9 2444/4885CA1 3283/4885CA12 2758/4885 |
| US-20210213012-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER | CDK3, CDK4, CDK1 | CA9 1292/4885CA1 1856/4885CA12 2135/4885 |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | CA9 2826/4885CA1 3736/4885CA12 2915/4885 |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | CA9 2444/4885CA1 3283/4885CA12 2758/4885 |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | CDK3, CDK4, CDK1 | CA9 1292/4885CA1 1856/4885CA12 2135/4885 |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | CA9 2444/4885CA1 3283/4885CA12 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.